Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHIT1 | Q13231 | 11/20 | 0.51 |
| ▸ | CHIA | Q9BZP6 | 10/20 | 0.51 |
| ▸ | CHI3L1 | P36222 | 7/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.37 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.37 |
| ▸ | CHI3L2 | Q15782 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28692439 | 0.89 | KCNH2 (0.48) | CHIT1CHIACHI3L1KCNH2HCRTR1 | |
| SCHEMBL18589339 | 0.86 | CHIT1 (0.48) | CHIT1CHIACHI3L1KCNH2HCRTR1 | |
| SCHEMBL20747186 | 0.86 | CHIT1 (0.48) | CHIT1CHIACHI3L1KCNH2HCRTR1 | |
| SCHEMBL18607759 | 0.86 | CHIT1 (0.48) | CHIT1CHIACHI3L1KCNH2HCRTR1 | |
| SCHEMBL18607977 | 0.86 | CHIT1 (0.48) | CHIT1CHIACHI3L1KCNH2HCRTR1 | |
| SCHEMBL25385125 | 0.80 | CHIT1 (0.42) | CHIT1CHIACHI3L1KCNH2HCRTR1 | |
| SCHEMBL28692423 | 0.79 | CHIT1 (0.48) | CHIT1CHIACHI3L1KCNH2HCRTR1 | |
| SCHEMBL18577112 | 0.79 | CHIT1 (0.48) | CHIT1CHIACHI3L1KCNH2HCRTR1 | |
| SCHEMBL26605744 | 0.79 | CHIT1 (0.50) | CHIT1CHIACHI3L1KCNH2HCRTR1 | |
| SCHEMBL18577375 | 0.79 | CHIT1 (0.53) | CHIT1CHIACHI3L1KCNH2HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348516-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | MOLECURE S.A. (PL) | 2023-11-02 | — | — | US | disclosed |
| EP-4269400-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | Molecure SA (PL) | 2023-11-01 | — | — | EP | disclosed |
| US-20230278996-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | MOLECURE S.A. (PL) | 2023-09-07 | — | — | US | disclosed |
| CN-114174280-A | Substituted aminotriazoles useful as chitinase inhibitors | 昂科艾伦迪治疗法公司 | 2022-03-11 | — | — | CN | disclosed |
| US-20190345137-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | GALAPAGOS NV (BE) | 2019-11-14 | — | — | US | disclosed |
| US-10208020-B2 | Substituted amino triazoles useful as human chitinase inhibitors | Oncoarendi Therapeutics S.A. (PL) | 2019-02-19 | — | — | US | disclosed |
| EP-3344616-B1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | ONCOARENDI THERAPEUTICS SA (PL) | 2019-01-09 | — | — | EP | disclosed |
| US-20180258071-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | GALAPAGOS NV (BE) | 2018-09-13 | — | — | US | disclosed |
| EP-3344616-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | ONCOARENDI THERAPEUTICS S.A. (PL) | 2018-07-11 | — | — | EP | disclosed |
| US-9944624-B2 | Substituted amino triazoles useful as human chitinase inhibitors | Oncoarendi Therapeutics S.A. (PL) | 2018-04-17 | — | — | US | disclosed |
| US-20170066743-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | GALAPAGOS NV (BE) | 2017-03-09 | — | — | US | disclosed |
| WO-2017037670-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | OncoArendi Therapeutics Sp. z o.o. (PL) | 2017-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190345137-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | CHIA, CHIT1, AADAC | CHIT1 2/4885CHIA 1/4885CHI3L1 4/4885 |
| US-20230278996-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | CHI3L1, CHI3L2, CHIA | CHIT1 4/4885CHIA 3/4885CHI3L1 1/4885 |
| US-20230348516-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | CHI3L1, CHI3L2, CHIA | CHIT1 4/4885CHIA 3/4885CHI3L1 1/4885 |
| US-10208020-B2 | Substituted amino triazoles useful as human chitinase inhibitors | CHIA, CHIT1, AADAC | CHIT1 2/4885CHIA 1/4885CHI3L1 4/4885 |
| US-20170066743-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | CHIA, CHIT1, AADAC | CHIT1 2/4885CHIA 1/4885CHI3L1 4/4885 |
| US-20180258071-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | CHIA, CHIT1, AADAC | CHIT1 2/4885CHIA 1/4885CHI3L1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.